As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin patent bid

Chi­nese reg­u­la­tors on Fri­day signed off on the sec­ond ap­proval for Hutchmed’s on­col­o­gy drug su­r­u­fa­tinib af­ter a suc­cess­ful Phase III tri­al.

Known com­mer­cial­ly as Su­lan­da in Chi­na, the drug re­cent­ly ap­proved for ad­vanced pan­cre­at­ic neu­roen­docrine tu­mors al­so won ap­proval in Chi­na 7 months ago for the treat­ment of non-pan­cre­at­ic neu­roen­docrine tu­mors.

Hutchmed CEO Chris­t­ian Hogg said in a state­ment, “Since its launch in Jan­u­ary this year, pa­tients with ep­NETs have ben­e­fit­ed from treat­ment with su­r­u­fa­tinib through its unique mode of ac­tion by both in­hibit­ing an­gio­gen­e­sis and pro­mot­ing the body’s im­mune re­sponse against tu­mor cells.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER